Dual inhibition of MAPK11 and MAPK14 is currently being tested as a monotherapy or in combination with other agents, such as gemcitabine and carboplatin, for the treatment of glioblastoma, ovarian, and metastatic breast cancer. Here, MAPK14 is linked to glioblastoma.